Skip to main content

Table 2 Prognostic value of IGF1R cytoplasm intensity in Cohort I (a) and II (b)

From: Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer

a)
Cohort I DDFS univariable DDFS multivariableb
Variable N HR 95% CI p-valuea N HR 95% CI p-value
IGF1R cytoplasm (0–3, linear) 264 0.70 0.52-0.94 0.016 220 0.80 0.58-1.1 0.18
Node status (N + vs N0) 264 1.2 0.71-2.1 0.45 220 1.1 0.57-2.0 0.83
Tumor size (>20 mm vs ≤20 mm) 264 2.0 1.0-3.8 0.037 220 1.7 0.80-3.5 0.17
HER2 (pos vs neg) 232 2.0 1.0-3.8 0.037 220 1.3 0.69-2.7 0.39
ER (pos vs neg) 254 0.38 0.23-0.64 <0.001 220 0.56 0.31-1.0 0.062
Ki67 (>20% vs ≤20%) 261 2.4 1.4-3.9 0.001 220 1.5 0.79-2.7 0.23
Menopausal status (post vs pre) 264 0.32 0.19-0.53 <0.001 220 0.37 0.20-0.68 0.001
IGF1R membrane (0–3, linear) 264 0.58 0.39-0.86 0.007     
p-mTOR (0–3, linear) 264 0.94 0.78-1.1 0.54     
p-S6rp (0–3, linear) 264 0.97 0.75-1.3 0.84     
Age (years, linear) 264 0.97 0.94-0.99 0.003     
Histologic grade (3 vs 1–2) 261 2.2 1.3-3.6 0.003     
PgR (pos vs neg) 254 0.61 0.37-1.0 0.064     
b)
Cohort II DDFS univariable DDFS multivariable c
Variable N HR 95% CI p-value a N HR 95% CI p-value
IGF1R cytoplasm (0–3, linear) 206 0.87 0.52-1.5 0.61 179 1.0 0.59-1.8 0.91
Age (years, linear) 206 0.91 0.86-0.96 0.001 179 0.92 0.86-0.99 0.02
Tumor size (>20 mm vs ≤20 mm) 206 1.9 0.94-3.8 0.07 179 1.2 0.51-2.7 0.70
HER2 (pos vs neg) 193 6.0 2.9-13 <0.001 179 5.1 2.3-11 <0.001
ER (pos vs neg) 206 0.38 0.20-0.75 0.005 179 0.86 0.38-1.9 0.71
Ki67 (>20% vs ≤20%) 186 2.6 1.3-5.2 0.007 179 1.8 0.75-4.1 0.19
IGF1R membrane (0–3, linear) 206 0.87 0.53-1.4 0.57     
p-mTOR (0–3, linear) 205 0.94 0.72-1.2 0.66     
p-S6rp (0–3, linear) 206 1.2 0.75-2.1 0.41     
Histologic grade (3 vs 1–2) 204 2.7 1.4-5.2 0.004     
PgR (pos vs neg) 206 0.32 0.16-0.63 0.001     
  1. aP-value for Cox-regression.
  2. bMultivariable analysis adjusted for node positivity, tumor size, HER2, ER, Ki67 and menopausal status.
  3. cMultivariable analysis adjusted for age, tumor size, HER2, ER and Ki67.
\